{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/0185cea5-9e3b-4b82-a887-26f91f92765f/6b35302a-f76c-4e1d-bc9c-38e80a566c1d?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Coronapod: Why COVID antibody treatments may not be the answer","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9f3b71a8cbe675f3cedcb/61b9f40a7701000015817e62.png?height=200","description":"<p>In the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19.</p><p><br></p><p>But despite promising clinical trial results and several therapies having already been approved, antibody therapies have not yet played a large role in the fight against COVID-19. In this episode of Coronapod, we ask why.</p><p><br></p><p><em>News:&nbsp;</em><a href=\"https://www.nature.com/articles/d41586-021-00650-7\" rel=\"noopener noreferrer\" target=\"_blank\"><em>COVID antibody treatments show promise for preventing severe disease</em></a></p><p><br></p><p><em>News:&nbsp;</em><a href=\"https://www.nature.com/articles/d41586-020-02360-y\" rel=\"noopener noreferrer\" target=\"_blank\"><em>Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?</em></a></p><p><br></p><p><span class=\"ql-cursor\"></span><a href=\"https://go.nature.com/get-the-nature-briefing\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.</strong></a></p>","author_name":"Springer Nature Limited"}